SG10201508252PA - Method for activating helper t cell - Google Patents
Method for activating helper t cellInfo
- Publication number
- SG10201508252PA SG10201508252PA SG10201508252PA SG10201508252PA SG10201508252PA SG 10201508252P A SG10201508252P A SG 10201508252PA SG 10201508252P A SG10201508252P A SG 10201508252PA SG 10201508252P A SG10201508252P A SG 10201508252PA SG 10201508252P A SG10201508252P A SG 10201508252PA
- Authority
- SG
- Singapore
- Prior art keywords
- cell
- activating helper
- helper
- activating
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title 1
- 210000002443 helper t lymphocyte Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010225806 | 2010-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201508252PA true SG10201508252PA (en) | 2015-11-27 |
Family
ID=45927725
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202108581TA SG10202108581TA (en) | 2010-10-05 | 2011-10-04 | Method for activating helper t cell |
SG2013025622A SG189287A1 (en) | 2010-10-05 | 2011-10-04 | Method for activating helper t cell |
SG10201508252PA SG10201508252PA (en) | 2010-10-05 | 2011-10-04 | Method for activating helper t cell |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202108581TA SG10202108581TA (en) | 2010-10-05 | 2011-10-04 | Method for activating helper t cell |
SG2013025622A SG189287A1 (en) | 2010-10-05 | 2011-10-04 | Method for activating helper t cell |
Country Status (20)
Country | Link |
---|---|
US (2) | US10654892B2 (de) |
EP (1) | EP2626418B8 (de) |
JP (3) | JP6134139B2 (de) |
KR (3) | KR102079480B1 (de) |
CN (2) | CN105802910A (de) |
AR (1) | AR083295A1 (de) |
AU (1) | AU2011313327B2 (de) |
BR (1) | BR112013008230A2 (de) |
CA (1) | CA2813557C (de) |
CO (1) | CO6710946A2 (de) |
EA (1) | EA037547B1 (de) |
ES (1) | ES2849187T3 (de) |
IL (2) | IL225536B (de) |
MX (2) | MX361299B (de) |
MY (1) | MY170306A (de) |
NZ (2) | NZ703560A (de) |
SG (3) | SG10202108581TA (de) |
TW (2) | TWI608099B (de) |
WO (1) | WO2012046730A1 (de) |
ZA (1) | ZA201303056B (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005045027A1 (ja) | 2003-11-05 | 2005-05-19 | International Institute Of Cancer Immunology, Inc. | Wt1由来のhla−dr結合性抗原ペプチド |
ES2531142T3 (es) | 2005-10-17 | 2015-03-11 | Sloan Kettering Inst Cancer | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden |
WO2007120673A2 (en) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
WO2008105462A1 (ja) | 2007-02-27 | 2008-09-04 | International Institute Of Cancer Immunology, Inc. | ヘルパーt細胞の活性化方法およびそのための組成物 |
AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
US10654892B2 (en) * | 2010-10-05 | 2020-05-19 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
CN104684577B (zh) | 2012-01-13 | 2018-05-08 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽及其使用方法 |
CA2884366A1 (en) * | 2012-09-12 | 2014-03-20 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper t-cell receptor genes |
AR094026A1 (es) * | 2012-12-17 | 2015-07-08 | Otsuka Pharma Co Ltd | Metodo para activar la celula t helper |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
PT2945647T (pt) | 2013-01-15 | 2020-11-26 | Memorial Sloan Kettering Cancer Center | Péptidos imunogénicos wt-1 e métodos de uso dos mesmos |
NZ712148A (en) | 2013-03-29 | 2019-11-29 | Sumitomo Dainippon Pharma Co Ltd | Wt1 antigen peptide conjugate vaccine |
JP6005305B2 (ja) * | 2014-02-26 | 2016-10-12 | テラ株式会社 | Wt1抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤 |
CN107427581A (zh) | 2014-12-25 | 2017-12-01 | 株式会社癌免疫研究所 | T细胞群的改变方法 |
CN106565836B (zh) * | 2015-10-10 | 2020-08-18 | 中国科学院广州生物医药与健康研究院 | 高亲和力的可溶性pdl-1分子 |
US10899790B2 (en) | 2016-11-09 | 2021-01-26 | Osaka University | Method for modifying T cell population |
WO2018101309A1 (ja) * | 2016-11-30 | 2018-06-07 | 大日本住友製薬株式会社 | Wt1ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ |
CN111741972A (zh) * | 2017-12-27 | 2020-10-02 | 大日本住友制药株式会社 | Wt1衍生肽的缀合物和包含其的组合物 |
CN111788214B (zh) * | 2018-02-15 | 2021-06-22 | 国立大学法人旭川医科大学 | 癌症抗原肽 |
EP3841113A1 (de) * | 2018-08-22 | 2021-06-30 | Fred Hutchinson Cancer Research Center | Gegen kras- or her2-antigene gerichtete immunotherapie |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
CN102198266A (zh) | 1998-07-31 | 2011-09-28 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
MXPA01003344A (es) | 1998-09-30 | 2004-04-21 | Corixa Corp | Composiciones y metodos para inmunoterapia especifica de wt1. |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
EP1261711A2 (de) | 2000-02-22 | 2002-12-04 | Corixa Corporation | Zusammensetzungen und methoden zur diagnose und therapie von malignen mesotheliom |
ATE383375T1 (de) | 2001-03-22 | 2008-01-15 | Int Inst Cancer Immunology Inc | Wti-modifiziertes peptid |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
DE60238958D1 (de) | 2001-06-29 | 2011-02-24 | Chugai Pharmaceutical Co Ltd | Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom |
EP1447091A4 (de) | 2001-09-28 | 2008-02-13 | Institute Of Can International | Neues verfahren zur induktion von antigen-spezifischen t-zellen |
WO2003028758A1 (fr) | 2001-09-28 | 2003-04-10 | Haruo Sugiyama | Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene |
AU2003242305A1 (en) | 2002-06-12 | 2003-12-31 | Chugai Seiyaku Kabushiki Kaisha | Hla-a24-restricted cancer antigen peptide |
JP4611022B2 (ja) | 2002-09-12 | 2011-01-12 | 株式会社癌免疫研究所 | 癌抗原ペプチド製剤 |
JP4480580B2 (ja) | 2002-09-20 | 2010-06-16 | 株式会社癌免疫研究所 | Wt1置換型ペプチド |
CN1756763B (zh) | 2003-01-15 | 2010-05-26 | 株式会社国际癌症免疫研究所 | 二聚体化肽 |
EP1640458B1 (de) | 2003-06-27 | 2011-12-28 | International Institute of Cancer Immunology, Inc. | Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff |
WO2005045027A1 (ja) | 2003-11-05 | 2005-05-19 | International Institute Of Cancer Immunology, Inc. | Wt1由来のhla−dr結合性抗原ペプチド |
US7622119B2 (en) | 2004-03-31 | 2009-11-24 | International Institute Of Cancer Immunology, Inc. | Cancer antigen peptides derived from WT1 |
US7608769B2 (en) * | 2004-05-12 | 2009-10-27 | First Act, Inc. | Packaged drum set |
JP4719876B2 (ja) | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Hlaクラスii拘束性wt1抗原ペプチド |
ES2531142T3 (es) | 2005-10-17 | 2015-03-11 | Sloan Kettering Inst Cancer | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden |
PT1961761E (pt) | 2005-11-30 | 2010-12-16 | Chugai Pharmaceutical Co Ltd | Novos compostos peptídicos do tumor de wilms |
US7420880B2 (en) | 2005-12-29 | 2008-09-02 | Timex Group B.V. | Multimode electronic device with calibrating/setting mechanism |
CN101384716B (zh) | 2006-02-22 | 2013-03-13 | 株式会社癌免疫研究所 | Hla-a*3303限制性wt1肽和包含此肽的药物组合物 |
WO2007120673A2 (en) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and methods of use thereof |
WO2008081701A1 (ja) | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Hla-a*1101拘束性wt1ペプチド、およびそれを含む医薬組成物 |
WO2008105462A1 (ja) | 2007-02-27 | 2008-09-04 | International Institute Of Cancer Immunology, Inc. | ヘルパーt細胞の活性化方法およびそのための組成物 |
CN103374576A (zh) | 2007-03-05 | 2013-10-30 | 株式会社癌免疫研究所 | 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用 |
AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
US10654892B2 (en) * | 2010-10-05 | 2020-05-19 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
AR094026A1 (es) | 2012-12-17 | 2015-07-08 | Otsuka Pharma Co Ltd | Metodo para activar la celula t helper |
-
2011
- 2011-10-04 US US13/877,768 patent/US10654892B2/en active Active
- 2011-10-04 NZ NZ703560A patent/NZ703560A/en unknown
- 2011-10-04 SG SG10202108581TA patent/SG10202108581TA/en unknown
- 2011-10-04 EA EA201390509A patent/EA037547B1/ru unknown
- 2011-10-04 BR BR112013008230A patent/BR112013008230A2/pt not_active Application Discontinuation
- 2011-10-04 AU AU2011313327A patent/AU2011313327B2/en active Active
- 2011-10-04 CN CN201610191489.4A patent/CN105802910A/zh active Pending
- 2011-10-04 KR KR1020197008457A patent/KR102079480B1/ko active IP Right Grant
- 2011-10-04 EP EP11830662.0A patent/EP2626418B8/de active Active
- 2011-10-04 CN CN201180058552.2A patent/CN103298928B/zh active Active
- 2011-10-04 WO PCT/JP2011/072874 patent/WO2012046730A1/ja active Application Filing
- 2011-10-04 CA CA2813557A patent/CA2813557C/en active Active
- 2011-10-04 JP JP2012537718A patent/JP6134139B2/ja active Active
- 2011-10-04 SG SG2013025622A patent/SG189287A1/en unknown
- 2011-10-04 TW TW100135857A patent/TWI608099B/zh active
- 2011-10-04 TW TW105107752A patent/TW201623616A/zh unknown
- 2011-10-04 MY MYPI2013001197A patent/MY170306A/en unknown
- 2011-10-04 ES ES11830662T patent/ES2849187T3/es active Active
- 2011-10-04 AR ARP110103676A patent/AR083295A1/es unknown
- 2011-10-04 MX MX2013003884A patent/MX361299B/es active IP Right Grant
- 2011-10-04 SG SG10201508252PA patent/SG10201508252PA/en unknown
- 2011-10-04 NZ NZ609460A patent/NZ609460A/en unknown
- 2011-10-04 KR KR1020137011554A patent/KR20140009168A/ko not_active Application Discontinuation
- 2011-10-04 KR KR1020207004213A patent/KR102171794B1/ko active IP Right Grant
-
2013
- 2013-04-02 IL IL225536A patent/IL225536B/en not_active IP Right Cessation
- 2013-04-05 MX MX2018008436A patent/MX2018008436A/es unknown
- 2013-04-25 ZA ZA2013/03056A patent/ZA201303056B/en unknown
- 2013-05-03 CO CO13111246A patent/CO6710946A2/es unknown
-
2016
- 2016-05-03 IL IL245440A patent/IL245440A0/en unknown
- 2016-05-31 JP JP2016109398A patent/JP6298101B2/ja active Active
-
2017
- 2017-12-12 JP JP2017237964A patent/JP2018093870A/ja active Pending
-
2020
- 2020-03-31 US US16/835,761 patent/US20200354405A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL245440A0 (en) | A method for activating a t-helper cell | |
EP2552873A4 (de) | Herstellungsverfahren für hexafluor-2-buten | |
GB201001833D0 (en) | Method | |
HK1216755A1 (zh) | 輔助性 細胞的活化方法 | |
GB201007353D0 (en) | Method | |
GB201007354D0 (en) | Method | |
GB201011513D0 (en) | Method | |
GB201004759D0 (en) | Method | |
EP2619169A4 (de) | Verfahren zur herstellung von bromharnstoff | |
EP2594552A4 (de) | Verfahren zur herstellung von ramalin | |
GB201012148D0 (en) | Method | |
GB201006306D0 (en) | Method | |
GB201010855D0 (en) | Method | |
GB201012784D0 (en) | Method | |
GB201007207D0 (en) | Method | |
EP2554659A4 (de) | Verfahren zur herstellung von es-zellen | |
GB201009136D0 (en) | Electrochemical method | |
GB201017003D0 (en) | Method | |
GB201007522D0 (en) | Method | |
IL225307A0 (en) | A method for the preparation of rumi urine | |
GB201016857D0 (en) | Culture method | |
GB201020072D0 (en) | Method | |
GB201017574D0 (en) | Method | |
GB201016858D0 (en) | Method | |
GB201016856D0 (en) | Method |